Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 129

    1.

    The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

    Masiello D, Gorospe G 3rd, Yang AS.

    J Hematol Oncol. 2009 Nov 12;2:46. Review.

    PMID:
    19909541
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Pleural effusions due to dasatinib.

    Brixey AG, Light RW.

    Curr Opin Pulm Med. 2010 Jul;16(4):351-6. Review.

    PMID:
    20375898
    [PubMed - indexed for MEDLINE]
    3.

    New approved dasatinib regimen available for clinical use.

    Snyder DS.

    Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. Review.

    PMID:
    19275507
    [PubMed - indexed for MEDLINE]
    4.

    Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

    Breccia M, Alimena G.

    Expert Opin Drug Saf. 2010 Sep;9(5):713-21. Review.

    PMID:
    20722490
    [PubMed - indexed for MEDLINE]
    5.

    Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

    McCormack PL, Keam SJ.

    Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

    PMID:
    21902298
    [PubMed - indexed for MEDLINE]
    7.

    First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

    Wei G, Rafiyath S, Liu D.

    J Hematol Oncol. 2010 Nov 26;3:47. Review.

    PMID:
    21108851
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

    Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P.

    Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8. Epub 2007 Jun 28.

    PMID:
    17600277
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

    Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J.

    J Clin Oncol. 2007 Sep 1;25(25):3908-14.

    PMID:
    17761974
    [PubMed - indexed for MEDLINE]
    10.

    Dasatinib-induced pleural effusions: a lymphatic network disorder?

    Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA.

    Am J Med Sci. 2009 Nov;338(5):414-7.

    PMID:
    19838099
    [PubMed - indexed for MEDLINE]
    11.

    Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

    Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

    Leukemia. 2008 Jun;22(6):1200-6. Epub 2008 Apr 10.

    PMID:
    18401416
    [PubMed - indexed for MEDLINE]
    12.

    Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.

    Shayani S.

    Ther Drug Monit. 2010 Dec;32(6):680-7. Review.

    PMID:
    20864900
    [PubMed - indexed for MEDLINE]
    13.

    Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

    Tyler T.

    Ann Pharmacother. 2009 May;43(5):920-7. Epub 2009 Mar 31. Review.

    PMID:
    19336654
    [PubMed - indexed for MEDLINE]
    14.

    Management of Bcr-Abl-positive leukemias with dasatinib.

    Hochhaus A.

    Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36. Review.

    PMID:
    18020922
    [PubMed - indexed for MEDLINE]
    15.

    Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

    Tinsley SM.

    J Clin Nurs. 2010 May;19(9-10):1207-18. Epub 2010 Mar 16. Review.

    PMID:
    20345830
    [PubMed - indexed for MEDLINE]
    16.

    Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.

    Jabbour E, Cortés JE, Kantarjian H.

    Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S75-81. Review.

    PMID:
    19254884
    [PubMed - indexed for MEDLINE]
    17.

    The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

    Visani G, Breccia M, Montefusco E, Morra E, Santini V, Isidori A.

    Haematologica. 2011 Apr;96(4):e23-4; author reply e25. No abstract available.

    PMID:
    21454871
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

    Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.

    Leukemia. 2008 Dec;22(12):2176-83. Epub 2008 Aug 28.

    PMID:
    18754032
    [PubMed - indexed for MEDLINE]
    19.

    Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

    Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y.

    Haematologica. 2011 Mar;96(3):e15; author reply e16-7. No abstract available.

    PMID:
    21357709
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

    Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E, Novakova L, Machova-Polakova K, Moravcova J, Dvorakova D, Michalova K, Brezinova J, Oltova A, Jarosova M, Cetkovsky P, Indrak K, Mayer J.

    Neoplasma. 2010;57(4):355-9.

    PMID:
    20429627
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk